KRAS and cancer: Twenty-eight of 42 recipient females (66%) had pulmonary metastases at the time of necropsy, and the co-expression of the nuclear GFP reporter is indicative for the sustained expression of oncogenic KRAS during the dissemination and metastatic growth of cancer cells (Fig. 1d).